Literature DB >> 16134130

A review of methods for futility stopping based on conditional power.

John M Lachin1.   

Abstract

Conditional power (CP) is the probability that the final study result will be statistically significant, given the data observed thus far and a specific assumption about the pattern of the data to be observed in the remainder of the study, such as assuming the original design effect, or the effect estimated from the current data, or under the null hypothesis. In many clinical trials, a CP computation at a pre-specified point in the study, such as mid-way, is used as the basis for early termination for futility when there is little evidence of a beneficial effect. Brownian motion can be used to describe the distribution of the interim Z-test value, the corresponding B-value, and the CP values under a specific assumption about the future data. A stopping boundary on the CP value specifies an equivalent boundary on the B-value from which the probability of stopping for futility can then be computed based on the planned study design (sample size and duration) and the assumed true effect size. This yields expressions for the total type I and II error probabilities. As the probability of stopping increases, the probability of a type I error alpha decreases from the nominal desired level (e.g. 0.05) while the probability of a type II error beta increases from the level specified in the study design. Thus a stopping boundary on the B-value can be determined such that the inflation in type II error probability is controlled at a desired level. An iterative procedure is also described that determines a stopping boundary on the B-value and a final test critical Z-value with specified type I and II error probabilities. The implementation in conjunction with a group sequential analysis for effectiveness is also described. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 16134130     DOI: 10.1002/sim.2151

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  54 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.

Authors:  William J Powers; William R Clarke; Robert L Grubb; Tom O Videen; Harold P Adams; Colin P Derdeyn
Journal:  JAMA       Date:  2011-11-09       Impact factor: 56.272

Review 3.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

4.  Optimal two-stage log-rank test for randomized phase II clinical trials.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  J Biopharm Stat       Date:  2016-04-06       Impact factor: 1.051

5.  Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.

Authors:  Richard R Love; Syed Mozammel Hossain; Md Margub Hussain; Mohammad Golam Mostafa; Adriano V Laudico; Stephen Sixto S Siguan; Clement Adebamowo; Jing-Zhong Sun; Fei Fei; Zhi-Ming Shao; Yunjiang Liu; Syed Md Akram Hussain; Baoning Zhang; Lin Cheng; Sonar Panigaro; Fardiana Walta; Jiang Hong Chuan; Maria Rica Mirasol-Lumague; Cheng-Har Yip; Narciso S Navarro; Chiun-Sheng Huang; Yen-Shen Lu; Tahmina Ferdousy; Reza Salim; Chameli Akhter; Shamsun Nahar; Gemma Uy; Gregory S Young; Erinn M Hade; David Jarjoura
Journal:  Eur J Cancer       Date:  2016-04-20       Impact factor: 9.162

6.  Conditional power as an aid in making interim decisions in observational studies.

Authors:  Alexander Muir Walker
Journal:  Eur J Epidemiol       Date:  2018-05-28       Impact factor: 8.082

7.  To stop or not to stop: a value of information view.

Authors:  Uwe Siebert; Lára R Hallsson
Journal:  Eur J Epidemiol       Date:  2018-08-17       Impact factor: 8.082

8.  A model-based conditional power assessment for decision making in randomized controlled trial studies.

Authors:  Baiming Zou; Jianwen Cai; Gary G Koch; Haibo Zhou; Fei Zou
Journal:  Stat Med       Date:  2017-09-04       Impact factor: 2.373

9.  A randomized trial of weekly symptom telemonitoring in advanced lung cancer.

Authors:  Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

10.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.